Close

Tricida (TCDA) Tops Q4 EPS by 4c

Go back to Tricida (TCDA) Tops Q4 EPS by 4c

Tricida Announces Fourth Quarter and Full-Year 2019 Financial Results

February 27, 2020 4:05 PM EST

Webcast Today at 4:30 pm Eastern Time

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today financial results for the fourth quarter and full-year ended December 31, 2019 and provided an update on key initiatives.

2019 Highlights

The U.S. Food and Drug Administration (FDA) accepted for review, through the... More